anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Approximately 30% of patients with schizophrenia have symptoms that persist despite multiple antipsychotic medication trials including clozapine, and there is currently no evidence-based treatment option for this population. These patients often suffer psychological distress related to their psychotic symptoms, become chronically disabled, and are unable to lead meaningful lives. Several promising new treatment modalities are being explored including deep brain stimulation (DBS) in subjects with treatment-resistant schizophrenia. A pilot study at another institution is using DBS of the substantia nigra pars reticulata (SNr) to modulate circuitry in the thalamus by disinhibiting the mediodorsal (MD) nucleus of the thalamus. This approach follows evidence from multiple structural and functional studies implicating hypofunction of the MD thalamus in the pathophysiology of schizophrenia. This includes an association between MD hypofunction and both positive and cognitive symptoms of schizophrenia including auditory hallucinations and working memory, respectively. As DBS is an invasive neurosurgical procedure with small but definable risks of neurologic injury, a minimally invasive screening method to optimize patient selection for DBS would be optimal.

This pilot study aims to investigate the use of MRI-guided low-intensity focused ultrasound (LIFU) to modulate neuronal activity within the thalamus in human subjects with treatment-resistant schizophrenia. Focused ultrasound itself is a safe, incisionless technology with high spatial resolution and depth penetration that has been shown to stimulate and inhibit neuronal activity. At high intensities, focused ultrasound can be used to thermally ablate a specific region of brain tissue and has been FDA-approved for the treatment of essential tremor and tremor in Parkinson's disease via thermal ablation of the ventral intermediate (VIM) thalamus. In contrast, LIFU is non-ablative and thus can be used for transient neuromodulation with high spatial precision due to direct real-time MRI targeting. This pilot study aims to use non-ablative LIFU to target the MD thalamus noninvasively and specifically, with the aim of interrogating and modulating the neuronal circuitry involved in symptoms of schizophrenia.
The recommended dose (RD) for Proxinium is to be determined based on the rate of Dose Limiting Toxicities (DLT) within each dose cohort. The RD is to be established as the highest dose at which one or fewer patients out of six within a dose cohort experienced a DLT. The initial dose level is 500 μg of Proxinium in PBS (the amount of PBS used will be based on the estimated volume of the target tumour). Doses are to be escalated to a maximum of 700 μg or de-escalated to a minimum of 260 μg according to the prescribed algorithm outlined in the study protocol.
BACKGROUND: The complex structure of the sole of the foot makes the repair of extensive defects challenging. The present study, therefore, aimed to address a gap in current research by evaluating the potential of the lateral thoracic free flap, including perforator options and chimeric configurations, to be used as an advanced solution for comprehensive sole reconstruction.
PATIENTS AND METHODS: We retrospectively collected the following data from the charts of patients with sole defects, due to various causes, who underwent lateral thoracic free tissue transfers: patient demographics; etiologies; comorbidities; flap types and dimensions; pedicle length; operative time; follow-up period; complications; and management.
RESULTS: The present study included 54 patients who underwent lateral thoracic free tissue transfer, citing infection, trauma, tumor, and posttraumatic sequelae as the major etiologies. We used the following techniques for the reconstruction of sole defects: thoracodorsal artery perforator free flap (83.3%); latissimus dorsi musculocutaneous free flap (1.9%); and various chimeric pattern flaps (14.8%). Free tissue transfer in the lateral thoracic region offers versatility for reconstruction, as well as low donor site morbidity. Complications observed in the present study included wound dehiscence (9.3%), partial necrosis (9.3%), and pressure ulcers (22.2%), although most patients healed favorably without flap loss.
CONCLUSIONS: The lateral thoracic free flap is a viable option for the reconstruction of the sole of the foot and allows for the effective reconstruction of complex defects. It contains a sustainable skin paddle, and multiple components can be easily included as a chimeric type. Further studies should seek to identify ways to prevent pressure ulcers, which was the only known long-term complication in the present study.
PURPOSE: To obtain a composition for controlling the color of skin, capable of changing a deep color part such as a stain or a freckle into an inconspicuous color part by compounding a substance having a yellow-red color interference color. CONSTITUTION: A substance having a yellow-red interference color is compounded in an amount of >=2wt.%, preferably >=10wt.%, based on the whole powder amount in the composition. The substance having the yellow-red interference color is preferably mica covered with a titanium dioxide-having titanium compound layer having an optical film thickness of 190-270nm and/or an optical film thickness of 410-500nm layer. In particular the titanium compound layer preferably contains titanium oxide nitride and/or a lower grade titanium oxide. The composition can change a deep skin color into an inconspicuous skin color in a natural form without deteriorating the transparent appearance of the skin.  The employment of the mica titanium containing the titanium oxide nitride and/or the low grade titanium oxide can give a finish appearance which is free from a brightness due to the luster of a pearl agent, which is a natural transparent appearance, and in which the deep color skin part has a color substantially equal to that of a normal color part.
The varicella-zoster virus (VZV) which causes herpes zoster (HZ), or shingles, is associated with a painful skin rash and post-herpetic neuralgia (PHN). The incidence and severity of HZ and PHN increase as immune function decreases, as in elderly or HIV-infected people. The live VZV vaccine, ZOSTAVAX, has been shown to reduce the incidence and severity of HZ and PHN in people over the age of 60. The main purpose of this study is to determine whether a two-dose regimen of ZOSTAVAX is safe and well-tolerated in HIV-infected individuals with conserved immune function.

This study has two stages and two arms. It may last up to 24 weeks per subject. In Stage 1, 48 participants with CD4 cell counts of 200 or more cells/uL will be enrolled (24 participants with a CD4 count between 200 and 349 cells/uL and 24 participants with a CD4 count equaling 350 or more cells/uL). These participants will be randomized 3:1 to receive two doses of ZOSTAVAX or placebo at least six weeks apart. If certain safety criteria are met for Stage 1, enrollment will be opened to Stage 2. Stage 2 will enroll approximately 352 subjects with CD4+ T cell counts \>= 200 cells/uL. In Stage 2, participants will be stratified using the same parameters as Stage 1 and will then be randomized 3:1 to receive either two doses of vaccine or placebo according to the same schedule. Participants will be followed for at least 42 days after each vaccination. Temperatures will be collected daily for 42 days following each vaccination. Telephone contact will also be made 2 to 3 days after each vaccination and at 24 weeks following the initial vaccination to obtain information regarding vaccination-related symptoms.

All participants will have between 6 and 8 study visits. At the screening visit, documentation of HIV status is required, and blood and urine collection, a physical exam, medical history, and clinical assessment will occur. At each visit, a targeted physical exam will occur. At some visits, blood and urine collection, and a clinical assessment will occur. Antiretroviral medications are not provided by this study.
The running training for interval group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine. The interval training group intensities ranged between 84-87% of maximal heart rate (HRmax) (vigorous intensity), 88-93%HRmax (near maximum intensity) and 94-99% HRmax (maximum intensity).
BACKGROUND: There is lack of research on corticosteroid use for severe and critical COVID-19 patients with Omicron variant infection.
METHODS: This multi-center retrospective cohort study involved 1167 patients from 59 ICUs across the mainland of China diagnosed with severe or critical SARS-CoV-2 Omicron variant infection between November 1, 2022, and February 11, 2023. Patients were segregated into two groups based on their corticosteroid treatment-usual dose (equivalent prednisone dose 30-50 mg/day) and higher dose (equivalent prednisone dose > 50 mg/day). The primary outcome was 28-day ICU mortality. Propensity score matching was used to compare outcomes between cohorts.
RESULTS: After propensity score matching, 520 patients in the usual dose corticosteroid group and 260 patients in the higher dose corticosteroid group were included in the analysis, respectively. The mortality was significantly higher in the higher dose corticosteroid group (67.3%, 175/260) compared to the usual dose group (56.0%, 291/520). Logistic regression showed that higher doses of corticosteroids were significantly associated with increased mortality at 28-day (OR = 1.62,95% CI 1.19-2.21, p = 0.002) and mortality in ICU stay (OR = 1.66,95% CI 1.21-2.28, p = 0.002). Different types of corticosteroids did not affect the effect.
CONCLUSIONS: The study suggests that higher-dose corticosteroids may lead to a poorer prognosis for severe and critical COVID-19 patients with Omicron variant infection in the ICU. Further research is needed to determine the appropriate corticosteroid dosage for these patients.
To evaluate the fetal ductus arteriosus anomalies diagnosed by fetal echocardiography. The perinatal outcomes and associated cardiac and genetic anomalies are also explored. The fetal echocardiography records of 2366 fetuses were evaluated retrospectively. Thirty-seven pregnancies prenatally diagnosed with ductus arteriosus anomalies and evaluated after delivery were enrolled in the study. Perinatal and obstetric outcomes were analyzed. The incidence of ductus arteriosus anomaly in our series was 1.5% (37/2366). The most frequent ductus arteriosus anomaly detected was right-sided ductus arteriosus followed by aneurysm, constriction and bilateral ductus arteriosus with an incidence of 51.3%, 27.1%, 18.9% and 2.7%, respectively. There were 19 fetuses with right-sided ductus arteriosus, of which 15 had tetralogy of Fallot. There were 2 chromosomal anomalies (22q11 microdeletion) in this group. Of the 7 fetuses with ductus arteriosus constriction, 3 (3/7, 42.9%) died in-utero. There were 2 (2/10, 20%) neonatal deaths due to hypoplastic left heart syndrome in the ductus arteriosus aneurysm group. Various types of ductus arteriosus anomalies can be diagnosed prenatally. Perinatal outcomes mostly dependent on the type of the ductus arteriosus anomaly and accompanying cardiac malformations.
PURPOSE: To obtain an inhibitor of vascular restenosis containing wortmannin and its analog. CONSTITUTION: This inhibitor of vascular restenosis is obtained by including a compound represented by the formula (R is H or acetoxy; R' is a 1-6C alkyl) and its analog as an active ingredient. The compound represented by the formula is administered as such or can be compounded and formulated with a carrier, an excipient or a diluent, etc., into a dosage form for parenteral, transdermal, rectal, nasal or local intravenous administration, preferably oral administration and administered. The daily dosage thereof is 0.001-10 mg/kg. The vascular restenosis is a long-term complication following surgical intervention of blocked arteries by percutaneous transluminal coronary angioplasty, atherectomy, laser angioplasty and arterial bypass graft surgery and is capable of inhibiting the proliferation and/or migration of smooth muscles, treating and preventing the vascular restenosis.  The compound represented by the formula is obtained by culturing a cultured strain of a microorganism A24603.1.
FIELD: medicine. ^ SUBSTANCE: invention relates to veterinary science. The method involves intramuscular injections of oxytocin in dose 30-40 Units per a head twice every 4 hours, intrauterine administration of Iodolene 1 suppository per a head twice every 24 hours, intravenous administration of 40 % glucose in dose 200 ml and 10 % calcium chloride in single dose 100-150 ml per a head. In addition, 2.5 % emicidine is injected intramuscularly in dose 10 ml per a head once a day for 10 days starting from the initiation of treatment. ^ EFFECT: method enables providing higher clinical effectiveness and improving reproductive indicators in cows. ^ 2 tbl, 3 ex
The use of benzodiazepines, including XANAX XR, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see Drug Abuse and Dependence (9.2)]. 

Before prescribing XANAX XR and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of XANAX XR, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of XANAX XR along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.
The five-year survival for pancreatic ductal adenocarcinoma (PDAC) is less than 5% in spite of the advances in management of cancers in the last few decades. Endobiliary application of radiofrequency (RF) has been developed and used in patients with inoperable bile duct and pancreatic head adenocarcinomas presenting with biliary obstruction. (1, 2) Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) of pancreatic neoplasms has been proven to be well tolerated and safe, inducing a significant reduction in tumour size (3). Various techniques of EUS-guided tumour ablation have been described, including RF ablation, photodynamic therapy, laser ablation, and ethanol injection (4). Kahaleh et al. have demonstrated that Endoscopic ultrasound guided RF ablation (EUS-RFA) of the pancreatic head using Habib EUS-RFA catheter (EMcision Ltd, UK) through a 19-gauge needle was well tolerated in 5 Yucatan pigs and with minimum amount of pancreatitis (5). In a pilot clinical study, Pai et al showed either a complete response or at least a 50% reduction in tumours following application of radiofrequency ablation with the Habib™ EUS-RFA device in a group of eight patients with pancreatic cancers (3).
The invention relates to the field of biomedicine, in particular to an HLA-0201 restriction PADI4 epitope polypeptide and application thereof, and provides an HLA-0201 restriction PADI4 epitope polypeptide, the amino acid sequence of which is selected from the following (a) to (c): (a) YLTGVEISL, SEQ ID NO. 1; (b) CLEEKVCSL, SEQ ID NO. 2; (c) ELLKRELGL, SEQ ID NO. 3. According to the invention, the gene encoding the PADI4 epitope polypeptide comprises an expression vector of a PADI4 epitope polypeptide gene. The HLA-0201 restrictive PADI4 epitope polypeptide has strong affinity with HLA-0201, and the immunogenicity of the polypeptide is evaluated, so that the polypeptide can induce specific HLA-0201 restrictive cytotoxic T lymphocytes in peripheral blood of healthy people with positive HLA-0201, and is an immunogenic polypeptide naturally processed and presented by cells. The HLA-0201 restriction PADI4 epitope polypeptide induced antigen specific cytotoxic T lymphocyte has high killing activity and high IFN-gamma secretion capability.
Gliomas are invasive and aggressive tumors, which derive from glial or stem cells, and after neoplastic transformation, acquire glial cell characteristics. Treatment of high-grade gliomas includes measures to relieve symptoms and eliminate or control the tumor. Surgery, radiation, and chemotherapy are the most common options. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. CKD is a restrictive therapeutic diet consisting of a 4:1 ratio of fat-to-CHO and protein. Fat provides up to 90% of the caloric intake, while overall CHO intake is less than 50 g/day. CKD reducing blood glucose levels and increasing ketone body levels stimulates biochemical changes to achieve systemic ketosis. Though, evidence for CKD in clinical practice is still limited. This study focuses on the classic ketogenic diet (CKD), adjusted for each patient's energy needs by dieticians to achieve ketosis. The primary outcome is to assess the efficacy of CKD to extend the survival of patients with high-grade gliomas and brain metastases. Historical controls will be used to compare the outcome measurements.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to cyclosporin solution. The proposed cyclosporin solution contains cyclosporin, dextpantenol as dissolving agent and forming stable colloidal solution that can be diluted with water in any ratio without cyclosporine precipitation. Invention provides good absorption of biologically active substance after oral intake. EFFECT: enhanced medicinal properties of solution. 16 cl, 4 tbl, 4 ex
The invention relates to a preparation method of a traditional Chinese medicine for treating blurred vision type acute glomerulonephritis, belonging to the technical field of preparation methods of traditional Chinese medicines. At present, bendazol is generally adopted for treating blurred vision type acute glomerulonephritis, but bendazol can cause headache, hidrosis and fever feelings. The technical scheme adopted in the invention is as follows: taking dutchmanspipe root, radix curcumae, shaddock, immature bitter orange, orange, selfheal, the seed of feather cockscomb, pipewort, scouring rush, chrysanthemum, mentha haplocalyx, cicada slough, elephant hide, ophatherum gracile, butterflybush flower, mung bean, dandelion, red-spotted stonecrop, root of shortstalk slimptop meadowrue, fruticose breyniae, small-leaved desmodium, wintercherry, jeffersonia dubia, uniflower swisscentaury root, olive, small-leaved lemmaphyllum, creeping rostellularia herb, gamboges, potentilla discolor, trillium tschonoskii maxim, globe amaranth flower and liquorice, soaking the 32 kinds of traditional Chinese medicines in water, and decocting with slow fire, wherein the decocted liquid medicine is the traditional Chinese medicine for treating blurred vision type acute glomerulonephritis. The traditional Chinese medicine for treating blurred vision type acute glomerulonephritis has the advantages of short course of treatment and high cure rate. Assistant and guide are achieved so that the function is just right. Adverse reaction, allergic reaction and toxic reaction caused by Western medicine are avoided.
PURPOSE:To obtain the novel compound, having excellent germicidal action on a wide range of microorganisms and useful as a medical germicide or an agricultural and horticultural germicide. CONSTITUTION:The compound is expressed by the formula (R is methyl, t-butyl or methoxy), e.g. 2-(4-tolyl)-4-methyl-1,2,5thiadiazol-3(2H)--one. This compound expressed by the formula is obtained by reacting an alaninamide derivative with sulfur monochloride in the presence of an organic solvent (e.g. a polar solvent such as N-dimethylformamide or 1,3-dimethyl-2-imidazolidinone) at 0-4 deg.C for 1-12hr. Furthermore, the amounts of the reagents used for the reaction are 1 equiv. alaninamide derivative and 2-4 equiv. sulfur monochloride.
The subjects for the proposed study will be 180 currently smoking, treatment-seeking male veterans with alcohol and nicotine dependence. Ninety subjects will be randomized to the topiramate arm and 90 subjects will be randomized to the placebo group.
The geography and ethnically matched control group consisted of 146 unrelated healthy subjects. They were genotyped for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms.
A vehicular control system includes an electronic control unit (ECU) disposed at a vehicle. The system is in wireless communication with a remote server. A health monitoring sensor captures sensor data representative of a health condition of an occupant of the vehicle. The system, based on processing at the ECU of captured sensor data, transmits a first signal to the remote server based on the captured sensor data. Responsive to receiving the first signal, the remote server transmits a second signal to the system including at least one destination suitable to treat the health condition of the occupant. Based on the second signal, the system selects a target destination from the at least one destination and determines a path of travel between the vehicle's current geographic location and the target destination's geographic location. The system at least partially controls operation of the vehicle along the path of travel.
Budesonide, a component of SYMBICORT, will often help control asthma and COPD symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since budesonide is absorbed into the circulation and can be systemically active at higher doses, the beneficial effects of SYMBICORT in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose.

Because of the possibility of systemic absorption of inhaled corticosteroids, patients treated with SYMBICORT should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response.

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients, particularly when budesonide is administered at higher than recommended doses over prolonged periods of time. If such effects occur, the dosage of SYMBICORT should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids and for management of asthma symptoms.